Easom Eric, CEO of AN2 Therapeutics ($ANTX), made one open market purchase of shares worth $10,665 in the last year, with the latest on June 2, 2025. He ranks 4,223rd out of nearly 5,000 insiders for purchase volume, well below the average of $1.5 million across 3.3 transactions. No open market sales reported.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Stock Option (right to buy) | 225000 | $0.00 | 225,000.0000 | 30,276,230 | 9999.99% | 0.74% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | D | Stock Option (right to buy) | 249999 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.83% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | D | Stock Option (right to buy) | 225000 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.74% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | D | Stock Option (right to buy) | 267650 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.88% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Stock Option (right to buy) | 267650 | $0.00 | 267,650.0000 | 30,276,230 | 9999.99% | 0.88% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Stock Option (right to buy) | 249999 | $0.00 | 249,999.0000 | 30,276,230 | 9999.99% | 0.83% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Stock Option (right to buy) | 224500 | $0.00 | 224,500.0000 | 30,276,230 | 9999.99% | 0.74% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Common Stock | 112250 | $0.00 | 1,628,512.0000 | 30,276,230 | 7.40% | 0.37% |
| June 2, 2025 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | P | Common Stock | 10000 | $1.07 | 1,516,262.0000 | 29,828,227 | 0.66% | 0.03% |
| Feb. 26, 2025 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Stock Option (right to buy) | 290500 | $0.00 | 290,500.0000 | 29,828,227 | 9999.99% | 0.97% |
| Feb. 26, 2025 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Common Stock | 145250 | $0.00 | 1,506,262.0000 | 29,828,227 | 10.67% | 0.49% |
| Nov. 18, 2024 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | P | Common Stock | 50000 | $1.00 | 1,361,012.0000 | 29,841,169 | 3.81% | 0.17% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Common Stock | 99000 | $0.00 | 101,130.0000 | 23,600,107 | 4647.89% | 0.42% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Stock Option (right to buy) | 198000 | $0.00 | 198,000.0000 | 23,600,107 | 9999.99% | 0.84% |
| March 15, 2024 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Common Stock | 99000 | $0.00 | 1,311,012.0000 | 23,600,107 | 8.17% | 0.42% |
| Jan. 2, 2024 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | S | Common Stock | 2777 | $20.09 | 1,212,012.0000 | 23,600,107 | 0.23% | 0.01% |
| May 15, 2023 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | P | Common Stock | 10000 | $5.38 | 1,214,789.0000 | 0 | 0.83% | 0.00% |
| Feb. 23, 2023 | AN2 Therapeutics, Inc. | $ANTX | Easom Eric | Chief Executive Officer | A | Stock Option (right to buy) | 267650 | $0.00 | 267,650.0000 | 0 | 9999.99% | 0.00% |